Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $49000.0.

  • Foghorn Therapeutics' Cash from Financing Activities fell 9533.78% to $49000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $446000.0, marking a year-over-year decrease of 9957.77%. This contributed to the annual value of $105.4 million for FY2024, which is 582958.38% up from last year.
  • Per Foghorn Therapeutics' latest filing, its Cash from Financing Activities stood at $49000.0 for Q3 2025, which was down 9533.78% from $254000.0 recorded in Q2 2025.
  • Foghorn Therapeutics' Cash from Financing Activities' 5-year high stood at $103.2 million during Q2 2024, with a 5-year trough of $4000.0 in Q4 2024.
  • For the 5-year period, Foghorn Therapeutics' Cash from Financing Activities averaged around $6.9 million, with its median value being $254000.0 (2025).
  • As far as peak fluctuations go, Foghorn Therapeutics' Cash from Financing Activities tumbled by 9992.64% in 2022, and later skyrocketed by 10010000.0% in 2024.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Cash from Financing Activities stood at $21.7 million in 2021, then plummeted by 99.93% to $16000.0 in 2022, then skyrocketed by 1062.5% to $186000.0 in 2023, then crashed by 97.85% to $4000.0 in 2024, then skyrocketed by 1125.0% to $49000.0 in 2025.
  • Its last three reported values are $49000.0 in Q3 2025, $254000.0 for Q2 2025, and $139000.0 during Q1 2025.